Endo Pharmaceuticals Holdings Inc (ENDP) 60.96 $ENDP
13.9% Return Seen to Date on SmarTrend Endo Pharmaceuticals Call (ENDP)
Comtex SmarTrend(R) - Tue Apr 08, 11:22AM CDT
SmarTrend identified a Downtrend for Endo Pharmaceuticals (NASDAQ:ENDP) on March 24th, 2014 at $68.72. In approximately 2 weeks, Endo Pharmaceuticals has returned 13.89% as of today's recent price of $59.17.
Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Tue Apr 08, 7:02AM CDT
Endo International plc ("Endo" or the "Company") announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), has amended the terms of its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes"), for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes"), respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers") and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors"), and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Offer to Exchange (as defined below).
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Endo Pharmaceuticals Falls 4.50% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 07, 5:18PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $60.49 to a high of $64.69. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $63.76 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Sciences' Clonidine in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:25PM CDT
BioDelivery Sciences enrolled the first patient in the phase III RHAPSODY study that will evaluate clonidine topical gel for the treatment of pain associated with diabetic neuropathy.
Mylan Rejected In Bid To Acquire Sweden's Meda
at Investor's Business Daily - Fri Apr 04, 11:27AM CDT
Generic-drug giant Mylan (MYL) on Friday lost out in a takeover bid for Swedish counterpart Meda, but its stock was still up more than 4% in midday trading on the stock market. Late Thursday, Britain's Financial Times reported that Mylan and Meda...
Watch for Endo Pharmaceuticals to Potentially Rebound After Falling 2.29% Yesterday
Comtex SmarTrend(R) - Thu Apr 03, 3:52PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $65.33 to a high of $68.59. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $66.00 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Sciences and Quintiles Sign Deal for Bunavail - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:30AM CDT
BioDelivery Sciences signs deal with Quintiles for supporting the anticipated launch of BioDelivery Sciences' Bunavail
Endo International plc Announces Endo Health Solutions Inc. Will Commence Exchange Offers
PR Newswire Europe - Thu Mar 27, 11:53PM CDT
Endo International plc ("Endo" or the "Company") announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), will commence offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI, which have an aggregate principal amount outstanding of $1.3 billion (collectively, the "Existing EHSI Notes"), for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes"), respectively, issued by Endo Finance LLC ("Endo Finance") and Endo Finco Inc. ("Endo Finco" and, together with Endo Finance, the "Endo Finance Issuers") and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors"). The exchange offers will commence on March 27, 2014 and will expire at 11:59 p.m., New York City time, on April 23, 2014, unless extended or terminated (the "Expiration Date"). The exchange of each series of the Existing EHSI Notes for the corresponding series of New Endo Finance Notes will be conducted on a par-for-par basis, subject to downward adjustment for tenders submitted after 11:59 p.m., New York City time, on April 9, 2014 (as it may be extended or terminated, the "Consent Date"). The terms and conditions of the exchange offers appear in the offering documents, which will be distributed to the holders of Existing EHSI Notes who complete and return a letter of eligibility confirming that they are "Eligible Holders" for the purposes of the exchange offers and the related consent solicitations. Endo expressly reserves the right to waive these conditions in whole or in part at any or at various times in its sole discretion.
Preventative Medicine Partnering 2009-2014 Report Out Now
M2 - Wed Mar 26, 11:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjvn7k/preventative) has announced the addition of the "Preventative Medicine Partnering 2009-2014" report to their offering. Preventative Medicine Partnering 2009-2014 report provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in preventative medicine partnering deals - Top preventative medicine deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type Preventative Medicine Partnering 2009-2014 provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of preventative medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors preventative medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preventative medicine technologies and products. Companies Mentioned: -Abbott -AstraZeneca -Baxter International -Bayer -Boehringer Ingelheim -Bristol-Myers Squibb -CSL -Daiichi Sankyo -Eli Lilly -Endo Pharmaceuticals -Forest Laboratories -Galderma -Gilead Sciences -Hospira -Johnson & Johnson -Kyowa Hakko Kirin -Lundbeck -Merck KGaA -Mitsubishi Tanabe -Novartis -Novo Nordisk -Otsuka -Pfizer -Roche -Sanofi -Shire -Takeda -Valeant -Warner Chilcott -Watson For more information visit http://www.researchandmarkets.com/research/xj...eventative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Look for Shares of Endo Pharmaceuticals to Potentially Rebound after Yesterday's 4.77% Sell Off
Comtex SmarTrend(R) - Mon Mar 24, 4:14PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.07 to a high of $71.36. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low of $70.71 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Health Car Sector Equities Technical Insight -- Research on Dynavax Technologies, Forest Laboratories, Orexigen Therapeutics and Endo Inl.
PR Newswire - Fri Mar 21, 9:08AM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:
Endo Pharmaceuticals Up 31.0% Since SmarTrend Uptrend Call (ENDP)
Comtex SmarTrend(R) - Wed Mar 19, 4:49PM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on November 5th, 2013 at $55.81. In approximately 4 months, Endo Pharmaceuticals has returned 31.01% as of today's recent price of $73.11.
Look for Shares of Endo Pharmaceuticals to Potentially Pullback after Yesterday's 3.53% Rise
Comtex SmarTrend(R) - Tue Mar 18, 4:25PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $71.08 to a high of $74.96. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $73.03 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Pipeline Update from BioDelivery Sciences - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:00PM CDT
BioDelivery Sciences provided updates on two of its lead candidates containing buprenorphine for opioid dependence and pain management, respectively.
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report
PR Newswire - Fri Mar 14, 5:30AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2013 financials and achievements as well as an update on business operations and upcoming milestones for 2014.
Endo Pharmaceuticals Has Returned 29.8% Since SmarTrend Recommendation (ENDP)
Comtex SmarTrend(R) - Wed Mar 12, 11:02AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on November 5th, 2013 at $55.81. In approximately 4 months, Endo Pharmaceuticals has returned 29.83% as of today's recent price of $72.45.
Insider Trading Alert - ENDP, AAPL And DTE Traded By Insiders
at The Street - Wed Mar 12, 9:00AM CDT
Stocks with insider trader activity include ENDP, AAPL and DTE
13.9% Return Seen to Date on SmarTrend Endo Pharmaceuticals Call (ENDP)
Comtex SmarTrend(R) - Tue Apr 08, 11:22AM CDT
SmarTrend identified a Downtrend for Endo Pharmaceuticals (NASDAQ:ENDP) on March 24th, 2014 at $68.72. In approximately 2 weeks, Endo Pharmaceuticals has returned 13.89% as of today's recent price of $59.17.
Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Tue Apr 08, 7:02AM CDT
Endo International plc ("Endo" or the "Company") announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), has amended the terms of its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes"), for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes"), respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers") and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors"), and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Offer to Exchange (as defined below).
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Endo Pharmaceuticals Falls 4.50% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 07, 5:18PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $60.49 to a high of $64.69. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $63.76 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Sciences' Clonidine in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:25PM CDT
BioDelivery Sciences enrolled the first patient in the phase III RHAPSODY study that will evaluate clonidine topical gel for the treatment of pain associated with diabetic neuropathy.
Mylan Rejected In Bid To Acquire Sweden's Meda
at Investor's Business Daily - Fri Apr 04, 11:27AM CDT
Generic-drug giant Mylan (MYL) on Friday lost out in a takeover bid for Swedish counterpart Meda, but its stock was still up more than 4% in midday trading on the stock market. Late Thursday, Britain's Financial Times reported that Mylan and Meda...
Watch for Endo Pharmaceuticals to Potentially Rebound After Falling 2.29% Yesterday
Comtex SmarTrend(R) - Thu Apr 03, 3:52PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $65.33 to a high of $68.59. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $66.00 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioDelivery Sciences and Quintiles Sign Deal for Bunavail - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:30AM CDT
BioDelivery Sciences signs deal with Quintiles for supporting the anticipated launch of BioDelivery Sciences' Bunavail
Endo International plc Announces Endo Health Solutions Inc. Will Commence Exchange Offers
PR Newswire Europe - Thu Mar 27, 11:53PM CDT
Endo International plc ("Endo" or the "Company") announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI"), will commence offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI, which have an aggregate principal amount outstanding of $1.3 billion (collectively, the "Existing EHSI Notes"), for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes"), respectively, issued by Endo Finance LLC ("Endo Finance") and Endo Finco Inc. ("Endo Finco" and, together with Endo Finance, the "Endo Finance Issuers") and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries (collectively, the "Guarantors"). The exchange offers will commence on March 27, 2014 and will expire at 11:59 p.m., New York City time, on April 23, 2014, unless extended or terminated (the "Expiration Date"). The exchange of each series of the Existing EHSI Notes for the corresponding series of New Endo Finance Notes will be conducted on a par-for-par basis, subject to downward adjustment for tenders submitted after 11:59 p.m., New York City time, on April 9, 2014 (as it may be extended or terminated, the "Consent Date"). The terms and conditions of the exchange offers appear in the offering documents, which will be distributed to the holders of Existing EHSI Notes who complete and return a letter of eligibility confirming that they are "Eligible Holders" for the purposes of the exchange offers and the related consent solicitations. Endo expressly reserves the right to waive these conditions in whole or in part at any or at various times in its sole discretion.
Preventative Medicine Partnering 2009-2014 Report Out Now
M2 - Wed Mar 26, 11:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjvn7k/preventative) has announced the addition of the "Preventative Medicine Partnering 2009-2014" report to their offering. Preventative Medicine Partnering 2009-2014 report provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies. - Trends in preventative medicine partnering deals - Top preventative medicine deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type Preventative Medicine Partnering 2009-2014 provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of preventative medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors preventative medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preventative medicine technologies and products. Companies Mentioned: -Abbott -AstraZeneca -Baxter International -Bayer -Boehringer Ingelheim -Bristol-Myers Squibb -CSL -Daiichi Sankyo -Eli Lilly -Endo Pharmaceuticals -Forest Laboratories -Galderma -Gilead Sciences -Hospira -Johnson & Johnson -Kyowa Hakko Kirin -Lundbeck -Merck KGaA -Mitsubishi Tanabe -Novartis -Novo Nordisk -Otsuka -Pfizer -Roche -Sanofi -Shire -Takeda -Valeant -Warner Chilcott -Watson For more information visit http://www.researchandmarkets.com/research/xj...eventative About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Look for Shares of Endo Pharmaceuticals to Potentially Rebound after Yesterday's 4.77% Sell Off
Comtex SmarTrend(R) - Mon Mar 24, 4:14PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.07 to a high of $71.36. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low of $70.71 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Health Car Sector Equities Technical Insight -- Research on Dynavax Technologies, Forest Laboratories, Orexigen Therapeutics and Endo Inl.
PR Newswire - Fri Mar 21, 9:08AM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:
Endo Pharmaceuticals Up 31.0% Since SmarTrend Uptrend Call (ENDP)
Comtex SmarTrend(R) - Wed Mar 19, 4:49PM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on November 5th, 2013 at $55.81. In approximately 4 months, Endo Pharmaceuticals has returned 31.01% as of today's recent price of $73.11.
Look for Shares of Endo Pharmaceuticals to Potentially Pullback after Yesterday's 3.53% Rise
Comtex SmarTrend(R) - Tue Mar 18, 4:25PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $71.08 to a high of $74.96. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $73.03 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Pipeline Update from BioDelivery Sciences - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:00PM CDT
BioDelivery Sciences provided updates on two of its lead candidates containing buprenorphine for opioid dependence and pain management, respectively.
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report
PR Newswire - Fri Mar 14, 5:30AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2013 financials and achievements as well as an update on business operations and upcoming milestones for 2014.
Endo Pharmaceuticals Has Returned 29.8% Since SmarTrend Recommendation (ENDP)
Comtex SmarTrend(R) - Wed Mar 12, 11:02AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on November 5th, 2013 at $55.81. In approximately 4 months, Endo Pharmaceuticals has returned 29.83% as of today's recent price of $72.45.
Insider Trading Alert - ENDP, AAPL And DTE Traded By Insiders
at The Street - Wed Mar 12, 9:00AM CDT
Stocks with insider trader activity include ENDP, AAPL and DTE
